Acalabrutinib: Same Survival Rates, But Better Tolerated Than Ibrutinib in CLL Treatment
Survival rates were similar between the 2 drugs, but acalabrutinib had fewer adverse events.
The Current and Future Landscape of PARP Inhibitors for Ovarian Cancer
An expert discusses how clinicians choose between PARP inhibitors for patients with ovarian cancer, and what may be coming next in the field.
GPRC5D CAR T Shows Safety, Efficacy in Pretreated R/R Multiple Myeloma
The Reality of VTE: How to Best Address in Cancer Care
AI Decision Support Tools Serve as Copilots in Cancer Care
Toxicity Monitoring, Management Crucial for Tarlatamab in ES-SCLC
